Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Victory Pharma, a privately held specialty pharmaceutical company in the US, has launched two additional dosage strengths of Naprelan controlled-release tablets.
Subscribe to our email newsletter
Naprelan is a once-daily, controlled-release formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of a number of conditions, including osteoarthritis, rheumatoid arthritis and management of mild to moderate pain.
Victory’s promotional efforts will be directed primarily at pain management specialists, rheumatologists, orthopedic surgeons and selected primary care physicians.
Since January 2007, Victory has promoted the 375mg dose of Naprelan. Victory plans to commence promotion on 500mg and 750mg Naprelan dose strengths by January 15, 2009.
Matt Heck, president and CEO of Victory Pharma, said: “By promoting these additional strengths of Naprelan, we will further leverage our commercial organization and provide the dosing flexibility sought by physicians treating pain and inflammation with NSAIDs.
“We believe Naprelan is an attractive option for pain management. Its active ingredient, naproxen sodium, has a well-established efficacy and safety profile, and its patented, controlled-release technology provides patients with the convenience of once-daily dosing.”